Table 3.

Cervical cytology findings by treatment group in intention to treat and per protocol populations

	Intention to treat population (517 women)			Per protocol population (517 women)
	Oral E2 plus Vaginal P4 (258 women)	Placebo (259 women)	Proportion Difference	Oral E2 plus Vaginal P4 (258 women)	Placebo (259 women)	Proportion Difference
Total abnormal cervical cytology	51, 19.8% (15.1%, 25.2%)	45, 17.4% (13.0%, 22.5%)	2.4% (−4.3%, 9.1%)	35, 13.6% (9.6%, 18.4%)	36, 13.9% (9.9%, 18.7%)	−0.3% (−6.2%, 5.6%)
Atypical squamous cells of undetermined significance	37, 14.3% (10.3%, 19.2%)	35, 13.5% (9.6%, 18.3%)	0.8% (−5.1%, 6.8%)	28, 10.8% (7.3%, 15.2%)	28, 10.8% (7.3%, 15.2%)	0% (−5.3%, 5.3%)
Atypical squamous cells cannot rule out high grade squamous intraepithelial cells	3, 1.2% (0.2%, 3.4%)	3, 1.2% (0.2%, 3.4%)	0% (−1.8%, 1.8%)	1, 0.4% (0%, 2.1%)	3, 1.1% (0.2%, 3.3%)	−0.8% (−2.3%, 0.7%)
Low grade squamous intraepithelial lesion	3, 1.2% (0.2%, 3.4%)	0, 0% (0%, 1.4%)	1.2% (−0.1%, 2.5%)	2, 0.8, (0%, 2.8%)	0, 0% (0%, 1.4%)	0.7% (−0.3%, 1.8%)
High grade squamous intraepithelial lesion	3, 1.2% (0.2%, 3.4%)	6, 2.3% (0.9%, 5.0%)	−1.1% (−3.4%, 1.1%)	1, 0.4% (0%, 2.1%)	4, 1.5% (0.4%, 3.9%)	−1.1% (−2.8%, 0.5%)
Atypical endocervical glandular cells of undetermined significance	9, 3.5% (1.6%, 6.5%)	2, 0.8% (0%, 2.8%)	2.7% (0.2%, 5.2%)	7, 2.7% (1.1%, 5.5%)	2, 0.8% (0%, 2.8%)	1.9% (−0.3%, 4.2%)

Data reported as number of women, proportion, 95%confidence interval of proportion

E2=estradiol, P4=progesterone